TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20731686

Group type: EXPERIMENTAL
Intervention: Aprotinin (280 mg load + 70 mg/hL) administered during donor lung perfusion and peri-operatively to recipients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo administered during donor lung perfusion and peri-operatively to recipients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aprotinin administration
Number of subjects: 48
Study: 19690556

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17003096

Group type: EXPERIMENTAL
Intervention: GH treatment 1 mg/m2.d
Number of subjects: 53
Study: 15502685

Group type: EXPERIMENTAL
Intervention: Corrective feedback
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Deception training
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Deception training plus feedback
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 11102422

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg daily
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 9181901

Group type: EXPERIMENTAL
Intervention: Urolase fiber (Bard) at 60 Watts for 60 seconds, administered to each lobe at 2, 4, 8 and 10 o'clock positions.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fibertom fiber (Dornier) using the 'painting' technique at 3 and 6 months.
Number of subjects: 100
Study: 8362533

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mini-incision cholecystectomy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Kocher's incision cholecystectomy
Number of subjects: 45
Study: 31865333

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training (20-min sessions, 3 days per week for 2 years)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 132
Study: 30685874

Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg daily starting 3 weeks pre-operatively, continued for 1 week after surgical haemostasis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVIG (1 to 2 g/kg administered 1 week pre-operatively, with allowance for a second dose within 1 week after surgical haemostasis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 0
Study: 28233944

Group type: EXPERIMENTAL
Intervention: Mylan-Nifedipine-XL
Number of subjects: 20
Study: 25957544

Group type: EXPERIMENTAL
Intervention: 15° external rotation brace (ER Group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: internal rotation sling (IR Group)
Number of subjects: 40
Study: 23253363

Group type: EXPERIMENTAL
Intervention: Working memory (WM) training program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Active control group conducting educational activities on memory
Number of subjects: 20
Study: 22083055

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 162

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 162
Study: 17909558

Group type: EXPERIMENTAL
Intervention: CESD‐20
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CESD‐10
Number of subjects: 47

Group type: COMPARATOR
Intervention: Short Form‐36 (SF‐36) subscales
Number of subjects: 47
Study: 15956010

Group type: EXPERIMENTAL
Intervention: Prednisolone (7.5 mg/d for 2 years)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 12540786

Group type: COMPARATOR
Intervention: Nadolol plus placebo (N + P)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nadolol plus spironolactone 100 mg/d (N + S)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nadolol plus spironolactone (N + S)
Number of subjects: 100
Study: 10803472

Group type: EXPERIMENTAL
Intervention: GHRH (1 microg/kg iv at 150 min) preceded by saline or GHRH at 0 min
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GHRH preceded by saline or rhGH (0.005 IU/kg iv at 0 min)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GHRH preceded by rhGH alone or combined with GHRH
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: HEX (2 microg/kg iv at 150 min) alone or preceded by rhGH
Number of subjects: 34
Study: 8639010

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering interventions (active intervention)
Number of subjects: 24968

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24968

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering interventions
Number of subjects: 24968
Study: 1705938

Group type: EXPERIMENTAL
Intervention: Group II (morphine group): hyperbaric 1% tetracaine with epinephrine and a single subarachnoid dose of Duramorph (morphine sulphate), 0.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group III (Dilaudid group): hyperbaric 1% tetracaine with epinephrine and a single subarachnoid dose of Dilaudid (hydromorphone hydrochloride), 0.002 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group I (control group): hyperbaric 1% tetracaine with epinephrine
Number of subjects: 60
Study: 6220729

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg and hyoscine 0.4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Papaveretum 20 mg and hyoscine 0.4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine-hyoscine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg and papaveretum 20 mg
Number of subjects: 0
Study: 31867643

Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes
Number of subjects: 68

Group type: COMPARATOR
Intervention: Reducing number of cigarettes per day (CPD)
Number of subjects: 68
Study: 30179958

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 130

Group type: COMPARATOR
Intervention: Hand-rasping technique
Number of subjects: 130
Study: 26418044

Group type: EXPERIMENTAL
Intervention: Computer-based auditory training program (12 weeks, 5 days/week)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard treatment for APD (control group)
Number of subjects: 39
Study: 25085020

Group type: EXPERIMENTAL
Intervention: Fennel (30 mg) soft capsule every 4 hours, 3 days before menstruation until the 5th day for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 80
Study: 22606852

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Number of subjects: 30
Study: 19237093

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg (b.i.d.), amoxicillin 1 g (b.i.d.), doxycycline 100 mg (b.i.d.)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg (b.i.d.), amoxicillin 1 g (b.i.d.), tetracycline 500 mg (q.i.d.)
Number of subjects: 115
Study: 17227905

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15356061

Group type: EXPERIMENTAL
Intervention: Repaglinide (1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glipizide (5 mg)
Number of subjects: 0
Study: 11265936

Group type: EXPERIMENTAL
Intervention: Telemedicine GPs (n = 126)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control GPs (n = 300)
Number of subjects: 426
Study: 9555920

Group type: EXPERIMENTAL
Intervention: Students who were given a rule for diagnosis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Students in the PT group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Students who were not given a rule
Number of subjects: 120
Study: 8087788

Group type: EXPERIMENTAL
Intervention: Androgen withdrawal, androgen blockade, or combination therapy (first-line treatment modalities)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 2659995

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine cream containing epidermal growth factor (10 micrograms per milliliter)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 12
Study: 31290550

Group type: EXPERIMENTAL
Intervention: Web-based cessation treatment for SM smokers
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Web-based cessation treatment for bisexual smokers
Number of subjects: 2637
Study: 31228618

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) plus pharmacotherapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard pharmacotherapy alone
Number of subjects: 102
Study: 28378301

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (integrated intervention incorporating social determinants of health)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Basic intervention (integrated intervention alone)
Number of subjects: 54
Study: 26074287

Group type: EXPERIMENTAL
Intervention: wound infiltration with 15 ml of ropivacaine 10%
Number of subjects: 400

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 400
Study: 23838478

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei F19 (LF19)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 21857268

Group type: EXPERIMENTAL
Intervention: Multiorifice catheter (2.5 cm)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Multiorifice catheter (5 cm)
Number of subjects: 153

Group type: COMPARATOR
Intervention: End-hole catheter (0.5 cm)
Number of subjects: 153
Study: 18930987

Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg) administered intravenously at weeks 0, 2, 6, and every 8 weeks thereafter to week 54
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (placebo) not explicitly mentioned in the outcomes
Number of subjects: 26
Study: 16757921

Group type: EXPERIMENTAL
Intervention: Symptomatic PAR
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: PAR
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: PAR (asymptomatic)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: PAR (symptomatic)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: PO
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Nasal allergy
Number of subjects: 232
Study: 14568836

Group type: EXPERIMENTAL
Intervention: Single treatment with topical 20% 5‐aminolevulinic acid for 3 hours or 14 to 18 hours followed by LP PDL irradiation at 595 nm
Number of subjects: 41

Group type: COMPARATOR
Intervention: LP PDL irradiation alone (control group)
Number of subjects: 41
Study: 10969448

Group type: EXPERIMENTAL
Intervention: Miacalcic (100 IU dose, intramuscularly)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcinin (100 IU dose, intramuscularly)
Number of subjects: 10
Study: 8784757

Group type: EXPERIMENTAL
Intervention: NaHCO3 (2 mEq.min‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1370511

Group type: EXPERIMENTAL
Intervention: Preseasonal alum-precipitated aqueous extracts of ragweed
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2578716

Group type: EXPERIMENTAL
Intervention: Trioxsalen bath PUVA
Number of subjects: 93

Group type: COMPARATOR
Intervention: Oral methoxsalen PUVA
Number of subjects: 93
Study: 30545775

Group type: EXPERIMENTAL
Intervention: Scleral lenses worn for 5 hours (Group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Scleral lenses worn for 20 minutes (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Scleral lenses worn for 5 hours (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Scleral lenses worn for 5 hours and 20 minutes
Number of subjects: 20
Study: 29330660

Group type: EXPERIMENTAL
Intervention: Theobromine (500 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: High-fat mixed meal
Number of subjects: 44
Study: 28383633

Group type: COMPARATOR
Intervention: Capecitabine (1250 mg/m2 for patients <70 years; 1000 mg/m2 for patients ≥70 years, twice daily on days 1-14)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: S-1 (30 mg/m2 orally twice daily on days 1-14)
Number of subjects: 161
Study: 26358345

Group type: EXPERIMENTAL
Intervention: Nasal triamcinolone acetonide 220 μg once daily for 28 days
Number of subjects: 149
Study: 22878130

Group type: EXPERIMENTAL
Intervention: High-output VNS stimulation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-output (active control) VNS stimulation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-output VNS stimulation (open-label phase)
Number of subjects: 41
Study: 21884606

Group type: EXPERIMENTAL
Intervention: Low dose vitamin A supplementation (VAS)
Number of subjects: 8626

Group type: COMPARATOR
Intervention: Recommended dose vitamin A supplementation (VAS)
Number of subjects: 8626
Study: 19994681

Group type: EXPERIMENTAL
Intervention: Catgut implantation at acupoint (Shenshu, Zigong, Sanyinjiao)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine group (oral administration of Diethylstilbestrol tablet)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Catgut implantation group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine group
Number of subjects: 60
Study: 17900050

Group type: EXPERIMENTAL
Intervention: ECT treatment (bitemporal ECT 3 times a week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Imipramine or desipramine (150-250 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ECT treatment
Number of subjects: 20
Study: 15573541

Group type: EXPERIMENTAL
Intervention: Automatic availability of task-related information
Number of subjects: 48

Group type: COMPARATOR
Intervention: Availability of task-related information upon request
Number of subjects: 48

Group type: COMPARATOR
Intervention: No availability of task-related information
Number of subjects: 48
Study: 11951995

Group type: EXPERIMENTAL
Intervention: New formula (<0.1 mg Fe 100 ml(‐1))
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard formula (0.5 mg Fe 100 ml(‐1))
Number of subjects: 149

Group type: COMPARATOR
Intervention: Breastfed reference group
Number of subjects: 149
Study: 9849711

Group type: EXPERIMENTAL
Intervention: Extra-amniotic balloon with intracervical PGE2 (0.5 mg x 2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Extra-ovular Foley catheter with intrauterine PGF2alpha (1 mg/h x 6)
Number of subjects: 68
Study: 7746297

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg b.i.d. for 4 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Ketoconazole 200 mg once-daily for 4 weeks
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 118
Study: 2563963

Group type: EXPERIMENTAL
Intervention: Nonenteric coated pancreatic enzyme supplement without ranitidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nonenteric coated pancreatic enzyme supplement with ranitidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enteric coated pancreatic enzyme supplements
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (baseline studies)
Number of subjects: 12
Study: 31913578

Group type: EXPERIMENTAL
Intervention: Hypertension defined by 140/90 mm Hg threshold
Number of subjects: 4515

Group type: EXPERIMENTAL
Intervention: Hypertension defined by 130/80 mm Hg threshold
Number of subjects: 4515
Study: 30735435

Group type: EXPERIMENTAL
Intervention: Chemotherapy with pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 0
Study: 28169880

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4071

Group type: COMPARATOR
Intervention: Control (discontinue all antihypertensive medications)
Number of subjects: 4071
Study: 25459101

Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 23172001

Group type: EXPERIMENTAL
Intervention: Problem-solving bibliotherapy intervention (PSBI)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 124
Study: 20179652

Group type: EXPERIMENTAL
Intervention: Core stability tests (flexion, extension, right and left lateral)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: T-run (TR)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Functional movement screen (FMS) tests (deep squat, trunk-stability push-up, right and left hurdle step, in-line lunge, shoulder mobility, active straight leg raise, rotary stability)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single leg squat (SLS)
Number of subjects: 28
Study: 19907103

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg/day for 12 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Amlodipine besilate 5 mg/day for 12 months
Number of subjects: 70
Study: 16491550

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 8888

Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg/day
Number of subjects: 8888
Study: 15519712

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 696

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study: 10644808

Group type: EXPERIMENTAL
Intervention: White cell-reduced irradiated blood (Group 1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-white-cell reduced irradiated blood (Group 2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison with healthy term infants (cord blood from 11 infants)
Number of subjects: 14
Study: 9062436

Group type: EXPERIMENTAL
Intervention: Self-administration of questionnaires
Number of subjects: 68
Study: 8383388

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (25 units, intramuscular)
Number of subjects: 0
Study: 6919664

Group type: EXPERIMENTAL
Intervention: One-to-one BSE instruction (experimental group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 30770758

Group type: EXPERIMENTAL
Intervention: L-theanine supplementation (150 mg for 6 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28205203

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination Training (CT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 60
Study: 25847306

Group type: EXPERIMENTAL
Intervention: Cumulative risk score of 15 or more
Number of subjects: 21575

Group type: EXPERIMENTAL
Intervention: Derivation group
Number of subjects: 21575

Group type: EXPERIMENTAL
Intervention: Validation group
Number of subjects: 21575
Study: 23945460

Group type: EXPERIMENTAL
Intervention: Life Goals Collaborative Care (LGCC)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 118
Study: 21059187

Group type: EXPERIMENTAL
Intervention: Parent intervention
Number of subjects: 2937

Group type: EXPERIMENTAL
Intervention: Combined parent-student intervention
Number of subjects: 2937

Group type: COMPARATOR
Intervention: Student intervention
Number of subjects: 2937

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2937
Study: 19296980

Group type: EXPERIMENTAL
Intervention: Intensive behavioral change intervention (226 participants)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Structured education program (112 participants)
Number of subjects: 338
Study: 17534246

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 103

Group type: COMPARATOR
Intervention: Pre-dilated stenting
Number of subjects: 103
Study: 16939738

Group type: EXPERIMENTAL
Intervention: Volume-controlled (VC) ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time-cycled pressure-limited (TCPL) ventilation
Number of subjects: 0
Study: 12904193

Group type: EXPERIMENTAL
Intervention: Clonidine 10-min group (3 microg x kg‐1 of clonidine administered for 10 min immediately after the spinal block)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Clonidine 60-min group (3 microg x kg‐1 of clonidine administered for 10 min, 50 min after the spinal block)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Clonidine 10-min group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 10498132

Group type: EXPERIMENTAL
Intervention: High-pressure postdilation (> or = 13 atm, group B)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Low-pressure implantation (6 to 12 atm, group A)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Angiographic follow-up
Number of subjects: 181
Study: 7854171

Group type: EXPERIMENTAL
Intervention: Enalapril (20 to 40 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1791391

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus 600 mg per day for 30 days
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus 1,200 mg per day for 30 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 6801079

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Calcium infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study: 30675745

Group type: EXPERIMENTAL
Intervention: Flaminal R Forte
Number of subjects: 89

Group type: COMPARATOR
Intervention: Flamazine R
Number of subjects: 89
Study: 28129661

Group type: EXPERIMENTAL
Intervention: Segmental re-examination of the proximal colon
Number of subjects: 360

Group type: COMPARATOR
Intervention: Extended withdrawal time (EWT)
Number of subjects: 360
Study: 26407698

Group type: EXPERIMENTAL
Intervention: 25 % silver nitrate (AgNO3) solution followed by 5 % sodium fluoride (NaF) varnish
Number of subjects: 1070

Group type: COMPARATOR
Intervention: 38 % silver diamine fluoride (SDF) solution
Number of subjects: 1070
Study: 23868537

Group type: EXPERIMENTAL
Intervention: Iron rich snacks cooked in iron pots
Number of subjects: 27
Study: 22214115

Group type: EXPERIMENTAL
Intervention: Multimedia-based educational interventions with authenticity strategy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Multimedia-based educational interventions with motivation strategy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 19486469

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (40 KDa) 180 microg/week plus ribavirin 1000/1200 mg/day for 48 weeks
Number of subjects: 569